Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
British healthcare technology firm Sensyne Health (SENS:AIM) has raised £60m to coincide with its stock market debut on 17 August. It will be valued at £225m when it starts trading on AIM.
Sensyne Health works with three NHS trusts by using its anonymous datasets for analysis, which can be used to improve patient care and speed up the discovery of new medicines.
It also licences its analysis to companies, which can help identify patients that may respond to certain treatments in clinical trials, identify new drug targets and help understand specific diseases.
Its NHS trust partners, Oxford, South Warwickshire and Chelsea & Westminster, collectively have a 10% stake in the company and receive 4% in royalties from licenced analysis.
The new money raised at its IPO (initial public offering) will be used to hire more doctors and computer scientists to analyse the data using clinical artificial intelligence and algorithms.
Sensyne has its sights set on 15 licences over the next few years, but investors should recognise potential risks such as competition and difficulty in attracting experts in artificial intelligence. (LMJ)
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.